Transient insight induction with electroconvulsive therapy in a patient with refractory schizophrenia: A case report and systematic literature review

Journal of ECT

Volumn 27, Issue 3, 2011, Pages 247-250

  Gerretsen, Philip ^a,b   Diaz, Pablo ^b,c   Mamo, David ^a,b   Kavanagh, Doug ^b   Menon, Mahesh ^a,c   Pollock, Bruce G ^a,b,d   Graff Guerrero, Ariel ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Schizophrenia Program   (Canada)

^d ROTMAN RESEARCH INSTITUTE   (Canada)

Author keywords

anosognosia; Electroconvulsive therapy; illness awareness; insight; schizophrenia

Indexed keywords

CLOZAPINE; FLUPHENAZINE DECANOATE; VALPROATE SEMISODIUM;

ADULT; ANOSOGNOSIA; AWARENESS; BEDTIME DOSAGE; CASE REPORT; DRUG DOSE TITRATION; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; HUMAN; MALE; NEUROLEPTIC MALIGNANT SYNDROME; REVIEW; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; AWARENESS; CLOZAPINE; COGNITION; DELUSIONS; DRUG RESISTANCE; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; EXECUTIVE FUNCTION; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TORTICOLLIS;

EID: 80052446035     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0b013e3181f816f6     Document Type: Review

References (39)

1. Olfson M, Marcus SC, Wilk J, et al. Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. Psychiatr Serv. 2006;57:205-211. (Pubitemid 43214466)
2. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. AWorld Health Organization ten-country study. Psychol Med Monogr Suppl. 1992;22:1-97.
3. Buckley PF, Wirshing DA, Bhushan P, et al. Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs. 2007;21:129-141.
4. Kemp R, David A. Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry. 1996;169(4):444-450.
5. Amador XF, Flaum M, Andreasen NC, et al Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994;51(10):826-836. (Pubitemid 24313308)
6. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544-549. (Pubitemid 29162974)
7. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52:805-811. (Pubitemid 32577440)
8. Opler LA, Caton CL, Shrout P, et al. Symptom profiles and homelessness in schizophrenia. J Nerv Ment Dis. 1994;182:174-178. (Pubitemid 24137671)
9. Swanson JW, Swartz MS, Borum R, et al. Involuntary out-patient commitment and reduction of violent behaviour in persons with severe mental illness. Br J Psychiatry. 2000;176:324-331.
10. Zygmunt A, Olfson M, Boyer CA, et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry. 2002;159:1653-1664.
11. Pekkala E, Merinder L. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2002;(2):CD002831.
12. O'Donnell C, Donohoe G, Sharkey L, et al. Compliance therapy: a randomised controlled trial in schizophrenia. BMJ. 2003; 327(7419):834.
13. David AS. Insight and psychosis. Br J Psychiatry. 1990;156:798-808. (Pubitemid 20207090)
14. Suzuki T, Uchida H, Takeuchi H, et al. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum Psychopharmacol. 2009;24(8): 628-638.
15. Rhoades HM, Overall JE. The semistructured BPRS interview and rating guide. Psychopharmacol Bull. 1988;24(1):101-104.
16. Amador X, Strauss D, Yale S, et al. Assessment of insight in psychosis. Am J Psychiatry. 1993;150:873-879. (Pubitemid 23156765)
17. Orfei MD, Robinson RG, Bria P, et al. Unawareness of illness in neuropsychiatric disorders: phenomenological certainty versus etiopathogenic vagueness. Neuroscientist. 2008;14(2):203-222. (Pubitemid 351348116)
18. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. (Pubitemid 41623495)
19. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
20. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988;39(11):1172-1177.
21. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
22. Schaul N, Lueders H, Sachdev K. Generalized, bilaterally synchronous bursts of slow waves in the EEG. Arch Neurol. 1981;38(11):690-692. (Pubitemid 11029557)
23. Milstein V, Small JG, Miller MJ, et al. Mechanisms of action of ECT: schizophrenia and schizoaffective disorder. Biol Psychiatry. 1990;27(12):1282-1292. (Pubitemid 20189976)
24. Sackeim HA, Luber B, Katzman GP, et al. The effects of electroconvulsive therapy on quantitative electroencephalograms. Relationship to clinical outcome. Arch Gen Psychiatry. 1996;53(9): 814-824.
25. Sackeim HA, Prudic J, Fuller R, et al. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology. 2007;32(1):244-254. (Pubitemid 44967804)
26. Mohamed S, Rosenheck R, McEvoy J, et al. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull. 2009;35(2):336-346.
27. Orfei MD, Robinson RG, Bria P, et al. Unawareness of illness in neuropsychiatric disorders: phenomenological certainty versus etiopathogenic vagueness. Neuroscientist. 2008;14:203-222. (Pubitemid 351348116)
28. Antoine C, Antoine P, Guermonprez P, et al. Awareness of deficits and anosognosia in Alzheimer's disease. Encephale. 2004;30:570-577.
29. Prigatano GP. Impaired self-awareness after moderately severe to severe traumatic brain injury. Acta Neurochir Suppl. 2005;93:39-42.
30. Prigatano GP. Disturbances of self-awareness and rehabilitation of patients with traumatic brain injury: a 20-year perspective. J Head Trauma Rehabil. 2005;20:19-29. (Pubitemid 40250683)
31. Ramachandran VS, McGeoch PD, Williams L. Can vestibular caloric stimulation be used to treat Dejerine-Roussy Syndrome? Med Hypotheses. 2007;69:486-488. (Pubitemid 47044953)
32. Shad MU, Muddasani S, Keshavan MS. Prefrontal subregions and dimensions of insight in first-episode schizophreniaVa pilot study. Psychiatry Res. 2006;146:35-42. (Pubitemid 43269986)
33. Flashman LA, McAllister TW, Johnson SC, et al. Specific frontal lobe subregions correlated with unawareness of illness in schizophrenia: a preliminary study. J Neuropsychiatry Clin Neurosci. 2001;13:255-257. (Pubitemid 32499678)
34. Shad MU, Muddasani S, Prasad K, et al. Insight and prefrontal cortex in first-episode schizophrenia. Neuroimage. 2004;22:1315-1320. (Pubitemid 38829220)
35. Aleman A, Agrawal N, Morgan KD, et al. Insight in psychosis and neuropsychological function: meta-analysis. Br J Psychiatry. 2006;189:204-212. (Pubitemid 44343464)
36. Subotnik K, Nuechterlein KH, Irzhevsky V, et al. Is unawareness of psychotic disorder a neurocognitive or psychological defensiveness problem? Schizophr Res. 2005;75:147-157. (Pubitemid 40693049)
37. Shad MU, Tamminga CA, Cullum M, et al. Insight and frontal cortical function in schizophrenia: a review. Schizophr Res. 2006;86: 54-70. (Pubitemid 44234058)
38. Rossell SL, Coakes J, Shapleske J, et al. Insight: its relationship with cognitive function, brain volume and symptoms in schizophrenia. Psychol Med. 2003;33(1):111-119. (Pubitemid 36113406)
39. Yen CF, Yeh ML, Chen CS, et al. Predictive value of insight for suicide, violence, hospitalization, and social adjustment for outpatients with schizophrenia: a prospective study. Compr Psychiatry. 2002;43(6): 443-447.